Clinical and in vitro effect of dornase alfa in mechanically ventilated pediatric non-cystic fibrosis patients with atelectases

Cellular Physiology and Biochemistry

Volumn 23, Issue 1-3, 2009, Pages 205-210

  Riethmueller, Joachim ^a   Kumpf, Matthias ^a   Borth Bruhns, Thomas ^a   Brehm, Wolfgang ^a   Wiskirchen, Jakub ^a   Sieverding, Ludger ^a   Ankele, Cosima ^a   Hofbeck, Michael ^a   Baden, Winfried ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Atelectasis; Children; Dornase alfa; Mechanical ventilation

Indexed keywords

DORNASE ALFA;

ARTICLE; ARTIFICIAL VENTILATION; ATELECTASIS; CHILD; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; IN VITRO STUDY; INFANT; INFLAMMATION; LUNG INFILTRATE; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; THORAX RADIOGRAPHY; TREATMENT RESPONSE;

EID: 60549113022     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000204109     Document Type: Article

References (38)

1. Peroni DG, Boner AL: Atelectasis: mechanisms, diagnosis and management. Paediatr Respir Rev Review 2000;1(3):274-278.
2. Shevland JE, Hirleman MT, Hoang KA, Kealey GP: Lobar collapse in the surgical intensive care unit. Br J Radiol 1983;56:531-534.
3. Galvis AG, Reyes G, Nelson W: Bedside Management of lung collaps in children on mechanical ventilation: Saline lavage -simulated cough technique proves simple, effective. Pediatr Pulmonol 1994;17:326-330.32.
4. Hamilton WK: Atelectasis, pneumothorax, and aspiration as postoperative complications. Anesthesiology 1961;22:708-722.
5. Reinhardt D: Therapie der Krankheiten im Kindes- und Jugendalter. Berlin, SpringerVerlag, 2004.
6. Wightman JAK: A prospective survey of the incidence of postoperative pulmonary complications. Br J Surg 1976;55:85-91.
7. Rivera R, Tibballs J: Complications of endotracheal intubation and mechanical ventilation in infants and children. Crit Care Med 1992;20(2):193-199.
8. Thomas K, Habibi P, Britto J, Owens CM: Distribution and pathophysiology of acute lobar collaps in the paediatric intensive care unit. Crit Care Med 1999;27(8):1594-1597.
9. Hendriks T, de Hoog M, Lequin MH, Devos AS, Merkus PJFM: DNase and atelectasis in non-cystic fibrosis pediatric patients. Crit Care Med 2005;9:351-356.
10. Riethmueller J, Borth-Bruhns T, Kumpf M, Vonthein R, Wiskirchen J, Stern M, Hofbeck M, Baden W: Recombinant human Deoxyribonuclease shortens ventilation time in young, mechanically ventilated children. Pediatr Pulmonol 2006;41:61-66.
11. Aitken ML, Burke W, McDonald G, Shak S, Montgomery AB, Smith A: Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study. JAMA 1992;267(14):1947-1951.
12. Harms HK, Matouk E, Tournier G, von der Hardt H, Weller PH, Romano L, Heijerman HG, Fitzgerald FX, Richard D, Strandvik B, Kolbe J, Kraemer R, Michalsen H: Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease. DNase International Study Group. Pediatr Pulmonol 1998:26(3):155-161.
13. Quan JM, Tiddens HAWM, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ, Wohl MEB, Konstan MW: A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001;139:813-820.
14. Shah PL, Scott SF, Knight RA, Marriott C, Ranashina C, Hodson ME: In vivo effect of rhDNase I on sputum in patients with cystic fibrosis. Thorax 1996;51(2):119-125.
15. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME: Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331:637-642.
16. Brandt T, Breitenstein S, von der Hardt H, Tümmler B: DNA concentration and length in sputum of patients with cystic fibrosis during inhalation with rhDNase. Thorax 1995;50(8):880-882.
17. Dasgupta B, King M: Reduction in viscoelasticity in cystic fibrosis sputum in vitro using combined treatment with nacystelyn and rhDNase. Pediatr Pulmonol 1996;22(3):161-166.
18. Dasgupta B, Brown NE, King M: Effects of sputum oscillations and rhDNase in vitro: A combined approach to treat cystic fibrosis lung disease. Pediatr Pulmonol 1998;26:250-255.
19. Kirchner KK, Wagener JS, Khan TZ, Copenhaver SC, Accurso FJ: Increased DNA levels in bronchoalveolavage fluid obtained from infants with cystic fibrosis. Am J Respir Crit Care Med 1996;154:1426-1429.
20. Rochat T, Pastore FD, Schlegel-Häuter SE, Filthuth I, Auckenthaler R, Belli D, Suter S: Aerolized rhDNase in cystic fibrosis: effect on leucocyte proteases in sputum. Eur Respir J 1996;9(11):2200-2206.
21. King M, Dasgupta B, Tomkiewicz RP, Brown NE: Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human desoxyribonuclease I. Am J Crit Care Med 1997;156(1):173-177.
22. Riethmueller J, Vonthein R, Borth-Bruhns T, Grassmé H, Eyrich M, Schilbach K, Stern M, Gulbins E: DNA Quantification and Fragmentation in Sputum after Inhalation of Recombinant Human Deoxyribonuclease. Cell Physiol Biochem 2008;22:347-352
23. Rubin BK: Who will benefit from DNase? Pediatr Pulmonol 1999;27:3-4.
24. Durward A, Forte V, Shemie SD: Resolution of mucus plugging and atelectasis after intratracheal rhDNase therapy in a mechanically ventilated child with refractory status asthmaticus. Crit Care Med 2000,28(2):560-562.
25. O'Donnell AE, Barker AF, Ilowite JS, Fick RB: Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. RhDNase Study Group. Chest 1998;113(5):1329-334.
26. Wills PJ, Wodehouse T, Corkery K, Mallon K, Wilson R, Cole PJ: Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability. Am J Respir Crit Care Med 1996;154(21):413-17.
27. Boeuf B, Prouix F, Morneau S, Marton D, Lacroix J: Safety of endotracheal rhDNase for treatment of pulmonary atelectasis in mechanically ventilated children. Pediatr Pulmonol 1998;26(2):147.
28. Shah PL, Scott SF, Knight RA, Marriott C, Ranashina C, Hodson ME: In vivo effect of rhDNase I on sputum in patients with cystic fibrosis. Thorax 1996;51(2):119-25.
29. Touleimat BA, Conoscenti CS, Fine JM: Recombinant human DNase in management of lobar atelectasis due to retained secretions. Thorax 1995;50(12):1319-321.
30. Voelker KG, Chetty KG, Mahutte CK: Resolution of recurrent atelectasis in spinal cord injury patients with administration of recombinant human DNase. Intensive Care Med 1996;22(6):582-84.
31. Desai M, Weller PH, Spencer DA: Clinical benefit from nebulized human recombinant DNase in Kartagener's syndrome. Pediatr Pulmonol 1995;20(5):307-308.
32. Ten Berge M, Brinkhorst G, Kroon AA, de Jongste JC: DNase treatment in primary ciliary dyskinesia-assessment by nocturnal pulse oximetry. Pediatr Pulmonol 1999;27:59-61.
33. Puchelle E, Zahm JM, de Nentzmann S, Grosskopf C, Shak S, Mougel D, Polu JM: Effects of rhDNase on purulent airway secretions in chronic bronchitis. Eur Respir J 1996;9(4):765-69.
34. El Hassan NO, Chess PR, Hysman MW, Merkus PJ, de Jongtse JC: Rescue use of DNase in critical lung atelectasis and mucus retention in premature neonates. Pediatrics 2001;108(2):468-470.
35. Reiter PD, Townsend SF, Velasquez R: Dornase alfa in premature infants with severe res-piratory distress and early bronchopulmonary dysplasia. J of Perinatology 2000;20:530-534.
36. Boogaard R, de Jongste JC, Merkus PJFM: Pharmacotherapy of Impaired Mucociliary Clearance in Non-CF Pediatric Lung Disease. A Review of the Literature. Pediatr Pulmonol 2007;42:989-1001.
37. Erdeve O, Uras N, Atasay B, Arsan S: Efficacy and Safety of Nebulized Recombinant Human DNase as Rescue Treatment for Persistent Atelectasis in Newborns: Case-series. Croat Med J 2007;48:234-239.
38. Merkus PJ, de Hoog M, van Gent R, de Jongste JC: DNase treatment for atelectasis in infants with severe respiratory syncytial virus bronchiolitis. Eur Respir J 2001;18:734-737.